報價延遲最少15分鐘:2025/07/18 17:48 EDT
盤後時段
|
||||
|
2.7307 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.76
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.04/-1.34
|
|
企業價值
248.92M
|
| 資產負債 |
|
每股賬面淨值
0.75
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
32.31M
|
|
每股收益
0.29
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 17:48 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
